Adjuvant therapies after curative treatments for hepatocellular carcinoma: Current status and prospects  

作　　者：Xiao-Dong Zhu Kang-Shuai Li Hui-Chuan Sun 

机构地区：[1]Department of Liver Surgery and Transplantation,Liver Cancer Institute and Zhongshan Hospital,Fudan University,Shanghai,200032,China

出　　处：《Genes & Diseases》2020年第3期359-369,共11页基因与疾病（英文）

基　　金：This work was supported by the Leading Investigator Program of Shanghai municipal government(17XD1401100);the National Key Basic Research Program(973 Program,2015CB554005)from the Ministry of Science and Technology of the People’s Republic of China;the National Natural Science Foundation of China(81372655,81472224 and 81672326)to HCS.

摘　　要：Tumor recurrence rate after surgery or ablation of hepatocellular carcinoma(HCC)is as high as 70%.However,there are no widely accepted adjuvant therapies;therefore,no treatment has been recommended by guidelines from the American Association for the Study of Liver Disease or the European Association for the Study of the Liver.All the registered trials failed to find any treatment to prolong recurrence-free survival,which is the primary outcome in most studies,including sorafenib.Some investigator-initiated studies revealed that antihepatitis B virus agents,interferon-a,transcatheter chemoembolization,chemokine-induced killer cells,and other treatments prolonged patient recurrence-free survival or overall survival after curative therapies.In this review,we summarize the current status of adjuvant treatments for HCC and explain the challenges associated with designing a clinical trial for adjuvant therapy.Promising new treatments being used as adjuvant therapy,especially anti-PD-1 antibodies,are also discussed.

关 键 词：Adjuvant therapy Anti-PD-1 antibody Clinical trial Hepatocellular carcinoma Molecular targeted therapy Recurrence-free survival 

分 类 号：R735.7[医药卫生—肿瘤]